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Evidence suggests that the Val66Met variant of the brain-derived
neurotrophic factor (BDNF) gene may play a role in the etiology
of Obsessive-Compulsive Disorder (OCD). In this study, the role
of the BDNF Val66Met variant in the etiology and the phenotypic
expression of OCD is investigated. Associations between the
BDNF Val66Met variant and OCD, obsessive-compulsive symp-
tom dimensions, Yale-Brown Obsessive Compulsive Scale
(YBOCS) severity scores, age of onset and family history of
obsessive-compulsive symptoms were assessed. The BDNF
Val66Met variant was genotyped in 419 patients with sub-/
clinical OCD and 650 controls. No differences in allele or geno-
type frequency were observed between cases and controls. In
females with OCD, the Met66Met genotype was associated with
later age of onset and a trend for a negative family history,
whereas the Val66Val genotype was associated with a trend for
lower YBOCS severity scores. Item-level factor analysis revealed
six factors: 1) Contamination/cleaning; 2) Aggressive obsessions/
checking; 3) Symmetry obsessions, counting, ordering and re-
peating; 4) Sexual/religious obsessions; 5) Hoarding and 6)
Somatic obsessions/checking. A trend was found for a positive
association between Factor 4 (Sexual/religious obsessions) and
the BDNF Val66Val genotype. The results suggest that BDNF
function may be implicated in the mediation of OCD. We found
that for the BDNF Met66Met genotype may be associated with a
milder phenotype in females and a possible role for the BDNF
Val66Val genotype and the BDNF Val66 allele in the sexual/
religious obsessions.  2009 Wiley-Liss, Inc.
Key words: obsessive-compulsive disorder; item-level factor
analysis; symptom dimensions; age of onset; Yale-Brown obses-
sive compulsive scale severity
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INTRODUCTION
Obsessive-compulsive disorder (OCD) is both clinically and ge-
netically heterogeneous. This heterogeneity obscures the findings of
clinical, natural, and treatment response studies. Family and twin
studies indicate that genetic factors play an important role in
mediating at least some forms of OCD [Pauls and Alsobrook,
1999; Hettema et al., 2001; Nestadt et al., 2002; van Grootheest
et al., 2005]. Although major advances have been made in the last
decade in characterizing the phenomenology and psychobiology of
OCD, its phenotypic and genetic heterogeneity has complicated the
search for vulnerability genes.
One approach to deal with this heterogeneity is to classify OCD
according to clinically defined characteristics and to search for the
genetic underpinnings of these possibly more homogeneous phe-
notypes. Most studies that focused on the phenomenology of
obsessive-compulsive (OC) symptoms used the Yale-Brown
Obsessive-Compulsive Scale symptom checklist (YBOCS-CL), a
screening instrument for the presence of frequently encountered
OC symptoms [Goodman et al., 1989a,b]. Factor analytic studies
using predefined symptom categories of the YBOCS-CL have
consistently found four OC symptom dimensions, namely (1)
aggressive, sexual, somatic and religious obsessions with checking
obsessions; (2) symmetry obsessions with ordering and arranging
compulsions; (3) contamination obsessions and cleaning compul-
sions, and (4) hoarding obsessions and compulsions [Miguel et al.,
2005]. These symptom dimensions are hypothesized to represent
more homogeneous genetic dimensions of OCD [Miguel et al.,
2005]. The YBOCS-CL symptom dimension of aggressive/sexual
obsessions and checking compulsions, and the symptom dimen-
sion of symmetry obsessions and ordering and arranging compul-
sions have been found to be more familial than the other symptom
dimensions [Alsobrook et al., 1999]. A recent family study showed
statistically significant correlations of scores on all symptom di-
mensions between affected sib pairs [Hasler et al., 2007]. Moreover,
a segregation analysis of the symptom dimensions in siblings with
Tourette syndrome (TS), a putative OCD spectrum disorder,
suggested a familial component for the symmetry, ordering and
counting factor as well as the aggression/sexual obsessions factor
[Leckman et al., 2003]. Furthermore, two recent genome scans in
which hoarding was used as a phenotype found suggestive linkage to
regions on chromosomes 14, 4q, 5q, and 17q [Zhang et al., 2002;
Samuels et al., 2007]. A recent candidate gene study recently found
the ‘‘obsessional/checking’’ OCD symptom subtype to be associat-
ed with earlier age of OCD onset and the Met158Met genotype of the
COMT Val158Met polymorphism [Lochner et al., 2008]. Three
studies investigated the relation between symptom dimensions and
an insertion/deletion polymorphism in the serotonin transporter
gene (5HTTP) [Cavallini et al., 2002; Kim et al., 2005; Hasler et al.,
2006]. Two of these studies found a trend for a positive association
between a symptom dimension with counting and repeating rituals
[Cavallini et al., 2002; Hasler et al., 2006]. The third study found an
association between this polymorphism and a factor with religious
and somatic obsessions [Kim et al., 2007]. Two other studies found
no association between symptom dimensions and the Val66Met
polymorphism in the Brain Derived Neurotrophic factor gene
(BDNF) [Wendland et al., 2007; Alonso et al., 2008]. Taken
together, these studies suggest that OC symptom dimensions
comprise distinct genetic entities, which would justify using them
as phenotypes in molecular genetic studies of OCD. Since the
symptom dimensions obtained by factor analysis can be quantified
as factor scores for each patient, these symptoms dimensions are
statistically more powerful than the investigation of OCD as a
dichotomous diagnostic entity [Silverman and Palmer, 2000].
The BDNF gene is an attractive OCD candidate gene, from both a
brain development and neurotransmitter perspective. BDNF has
been implicated in neuronal survival and in activity-dependent
neuroplasticity [Hennigan et al., 2007]. Studies in knockout mice as
well as those using B cell lines suggest that BDNF modulates the
serotonin transporter function [Mossner et al., 2000; Daws et al., 2007].
A polymorphism in the BDNF gene that causes a valine to
methionine substitution in the prodomain of the BDNF protein
(Val66Met) has been shown to reduce activity-dependent BDNF
secretion in transfected neurons [Egan et al., 2003]. Studies in
BDNF Met66Met mice suggest that this polymorphism may be
implicated in anxiety-related behaviors [Chen et al., 2006]. Phar-
macological and neurobiological studies suggest that the seroto-
nergic system is involved in the pathogenesis of OCD [Westenberg
et al., 2007]. In summary, there are several lines of evidence
indicating that the serotonergic system and, more specifically
BDNF, may be implicated in the etiology of OCD.
Thus far, seven studies have reported on the BDNF Val66Met
variant in OCD, using either a family based approach [Hall et al.,
2003; Mossner et al., 2005; Zai et al., 2005; Dickel et al., 2007], or a
case–control design [Wendland et al., 2007; Alonso et al., 2008;
Hemmings et al., 2008]. These studies are summarized in Table I.
Findings have been inconsistent. In the family based studies, an
under transmission of the BDNF Met66 allele was found in one
study of patients with childhood-onset OCD [Hall et al., 2003],
whereas the other studies did not show a preferential transmission
of either of the alleles. In the case–control studies an association was
found of the BDNF Met66 allele with OCD in males [Hemmings
et al., 2008], whereas Wendland et al. [2007] did not find an
association. One family based study using haplotype analysis found
a haplotype marked by the BDNF Met66 allele to be undertrans-
mitted and therefore likely to confer a protective effect against OCD
[Hall et al., 2003], whereas another family based study found a
haplotype including the BDNF Val66 allele to be associated with a
reduced risk for OCD [Alonso et al., 2008]. Some studies also
investigated the association of the BDNF Val66Met genotype and
dimensional OC phenotypes such as symptom dimensions, age of
onset and symptom severity [Hall et al., 2003; Zai et al., 2005;
Wendland et al., 2007; Alonso et al., 2008]. One study found an
association of the BDNF Met66 allele with earlier age of onset in
males and the BDNF Val66Met genotype with increased severity in
women [Hemmings et al., 2008], whereas other studies did not find
an association with these dimensional phenotypes. Similarly, a
family based study of the BDNF Val66Met in patients with TS
(with or without comorbid OCD), a disorder genetically related to
OCD, found no association between TS and the BDNF Val66Met
polymorphism [Klaffke et al., 2006].
An important drawback of the studies mentioned concerns the
relatively small sample sizes, which possibly explains the inconsis-
tent findings to date. In this study, trying to overcome this disad-
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vantage, we investigated the BDNF Val66Met polymorphism in a
large group of patients with OCD. The aims of our study were: (1) to
replicate the association of the BDNF Val66Met polymorphism and
OCD in patients with early-onset OCD and/or males described
previously [Hall et al., 2003; Hemmings et al., 2008] (2) to investi-
gate the association of this polymorphism with specific OC symp-
tom dimensions, age of onset of OC symptoms (irrespective of the
nature thereof), OC symptom severity and family history of OC
symptoms. Since sex differences have been described in both clinical
and genetic studies of OCD [Lochner et al., 2004; Labad et al., 2008],
we also investigated sex-specific associations of this polymorphism
with clinical characteristics of OCD.
METHODS
This project encompasses a joint venture between the Department
of Psychiatry of VU University Medical Center (VUMC) and the
Department of Psychiatry of the University Medical Center
Groningen (UMCG) in the Netherlands and the MRC Research
Unit on Anxiety Disorders, in collaboration with the MRC/US
Centre for Molecular and Cellular Biology, University of Stellen-
bosch in South Africa. The study was approved by the Medical
Ethical Review Boards of the participating centers. All patients (and
in case of minors, their parents) gave written informed consent for
participation in the study.
Participants
Patients at the MRC Unit on Anxiety and Stress disorders of the
University of Stellenbosch were recruited by physician referral,
media advertisements, the Mental Health Information Centre
(MHIC) and the OCD Association of South Africa (OCDSA), as
described previously [Hemmings et al., 2008]. Patients at the
outpatient Clinic for Anxiety Disorders, GGZ Buitenamstel in
Amsterdam and the University Medical Center in Groningen
(The Netherlands) were recruited by physician referral, media
advertisements and patient societies for patients with anxiety
disorders.
All patients met criteria for either a lifetime (Netherlands) or a
current (South Africa) diagnosis of OCD or subclinical OCD
according to DSM-IV criteria [American Psychiatric Association,
1994]. Diagnoses were established using the Structured Clinical
Interview for Axis I disorders (SCID-I/P) [First et al., 1998] or the
Mini International Neuropsychiatric Interview (MINI) version
5.0.0. [Sheehan et al., 1998]. Subclinical OCD was defined as OC
symptoms that are either time-consuming (i.e., take 1 hr a day or
more, but without causing distress) or interference or that are
distressing or causing interference, but take less than 1 hr a day.
Only Caucasian patients and controls from the South African site
were included; patients from the Netherlands were from the general
Dutch population. Control subjects from both South Africa and the
Netherlands encompassed an unscreened convenience sample re-
cruited from the general population. The study included 606
phenotyped patients of whom 419 (n¼ 220 from The Netherlands,
n¼ 199 from South Africa) were also genotyped for the BDNF
Val66Met polymorphism. YBOCS-CL data were available for 579
patients. Further, genotype data were available of 650 controls
(n¼ 535 Dutch, n¼ 115 Caucasian South African). Some of the
subjects from the South African cohort were included in a previous
case–control study [Hemmings et al., 2008].
Measurements
The YBOCS-CL [Goodman et al., 1989a,b] was used to assess OC
symptom characteristics. In some patients from Amsterdam
(n¼ 111) an extended 80-item self-response version of the YBOCS
was used. This 80-item self-report YBOCS-CL was translated from
the version used in the TSA genetica consortium on Tourette’s
disorder and within the scope of the OCF international collabora-
tion on the genetics of OCD. In a comparison of an interview-
versus self-report version of the YBOCS-CL in the US, the self-
report version showed good internal consistency and test-retest
reliability and strong convergent validity with the interview version
[Steketee et al., 1996].
Current severity of the obsessive-compulsive symptoms was
assessed using the YBOCS Severity Scale (YBOCS-SS) [Goodman
et al., 1989a,b]. In contrast to YBOCS-symptom checklist data,
we used the original interview-based severity scale as the YBOCS
severity scale. In addition, age of onset of OC symptoms and family
history of OC symptoms were determined. Family history was
considered to be positive if the proband reported the presence of
recognizable OC symptomatology that bothered the person in at
least one first-degree family member.
Genotyping
DNA was isolated from blood using a chloroform/isopropanol
extraction [Meulenbelt et al., 1995], from buccal swabs using a
salting out procedure [Miller et al., 1988] or from sputum using an
Oragene DNA self collection kit (DNA Genotek, Inc., Ottawa,
Canada) according to manufacturers instructions.
All DNA samples from the South African cohort were obtained
from blood. Genotyping of the South African cohort was performed
by allele-specific restriction enzyme digestion of a PCR product
with NlaIII, as described previously [Hemmings et al., 2008].
Complete digestion was taken to be the presence of the consecutive
57 bp band.
Dutch samples were genotyped in a SNPlex genotyping assay
(Applied Biosystems, Foster City, CA) or by Taqman geno-
typing assay (Applied Biosystems) (Assay on demand, ID
CD_11592758_10) according to manufacturer’s instructions.
All controls from the Dutch cohort were genotyped in a
SNPlex genotyping assay: 104 blood samples with a 100% success
rate and 450 buccal swab samples with 95.7% success rate. The
genotypes of the Dutch patients were determined in two SNPlex
runs with a mean success rate of 90.2% and a Taqman run with a
success rate of 94.7%.
Statistical Analysis
Data from the South African and Dutch cohorts were combined.
Power calculations were performed with the genetic power
calculator [Purcell et al., 2003] assuming a disease prevalence of
2% [Angst et al., 2004; Weissman et al., 1994]. Hardy–Weinberg
equilibrium was tested using chi square tests using Microsoft Office
Excel. Genotype and allele frequencies were compared between
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patients and controls and between patients with different pheno-
types using Fisher’s exact tests. Since data on continuous variables
such as age of onset of OC symptoms, YBOCS-SS score and factor
scores showed a skewed distribution, differences in these variables
between patients with different genotypes and between the BDNF
Val66 and the Met66 allele were examined using non-parametric
tests (Kruskal–Wallis and Mann–Whitney U tests).
Factor Analyses
Different versions of the YBOCS-CL were used with some non-
overlapping items. Only items overlapping with the 74-item
YBOCS-CL version described by Goodman et al. [1989a,b] were
used in the analysis. The extended 80-item self-report version of
YBOCS-CL used for some Dutch patients, contained several items
concerning obsessions with symmetry and exactness. However,
since no distinction was made with respect to magical thinking
accompanying these obsessions, one item was created coding for
any symmetry obsession in the patients. Moreover, in the 80-item
self report version of the YBOCS-CL seven items were not available
(as indicated in Table IV). Missing values in the YBOCS-CL and
YBOCS-SS were imputed using Solas 3.2 (Statistical Solutions,
Ltd, Cork, Ireland), using predictive model-based imputation. For
the YBOCS-CL only the items with missing values were included in
the imputation model whereas for the YBOCS-SS all items were
used in the imputation model. Five different datasets were imputed
according to recommendations by Schafer [1999]. Items from the
‘‘miscellaneous’’ or ‘‘other’’ categories were omitted from the
analysis since these symptoms were considered to be too
heterogeneous.
Explorative item-by-item level factor analysis with promax
rotation was performed using MPlus [Muthen and Muthen,
1998–2006]. Promax rotation was used, since this form of rotation
allows the factors to be correlated. Subsequently, confirmatory
factor analysis for categorical variables was performed to establish
the number of factors and factor constitution using the following
fit indices: the x2 statistic, the comparative fit index (CFI), the -
Tucker-Lewis Index (TLI), the Root Mean Square Error of
Approximation (RMSEA) and the Standardized Root Mean Square
Residual (SRMR). Values of the CFI and of TLI approaching
0.95, values approaching 0.08 of the SRMR and values of the
RMSEA< 0.05 are generally indicative of a good fit [Browne and
Cudek, 1993; Hu and Bentler, 1999].
For the best fitting model, mean score per item for each of the
obtained factors was calculated for each patient, representing
the prominence of this factor in the patient. Mean results for the
five imputed datasets are reported. Kruskal–Wallis tests and
Mann–Whitney U tests were performed to investigate whether
mean item score per factor were associated with the BDNF Val66-
Met genotype or alleles. Kruskal–Wallis tests and Mann–Whitney U
tests were performed using R statistical package [R Development
Core Team, 2008]. For these tests empirical P values were calculated
based on 1000 random permutations. This was done for the entire
sample and for male and female patients separately in order to
obtain robust P-values for each gender. Ten phenotypes were
tested (OCD as a dichotomous trait, age of onset of OC symptoms,
YBOCS severity score, family history and 6 symptom dimensions).
These phenotypes were tested for the entire sample and for males
and females separately. Because the total sample is not independent
from the two genders, a P-value of 0.05/20¼ 0.0025 was considered
significant for these tests. All statistical tests were performed using
the Software Package for Social Sciences (SPSS) version 14.0 (SPSS,
Inc, Chicago, IL) except noted otherwise.
Sample Size and Power Considerations
Since large samples produce more stable variable loadings across
repeated sampling and more precise estimates of population
loadings [MacCallum et al., 1999], we included non-genotyped
participants in the factor analysis as well.
Similarly, we included previously studied Caucasian subjects
from South Africa in our current association study to increase
sample size and power. Based on the allele frequency in our
combined control population, the power to detect a dominant
TABLE II. Demographic and Clinical Characteristics of the OCD Patients in the Different Cohorts
Total cohort South African cohort Dutch cohort P
All patients
n 606 199 407
Age (y, mean SD) 35.4 12.7 32.8 14.5 36.7 11.6 <0.001
Female (%) 334 (55.1%) 95 (47.7%) 239 (58.7%) 0.011
Age of onset (y, mean SD) 17.4 9.9 17.2 10.9 (n¼ 188) 17.5 9.3 (n¼ 366) 0.134
YBOCS severity (mean SD) 20.5 8.1 19.9 7.6 (n¼ 195) 20.7 8.3 (n¼ 392) 0.137
Positive family history of OC behavior (%) 94 (44.3%) (n¼ 212)
Genotyped patients
n 419 199 220
Age (y, mean SD) 35.3 13.4 32.8 14.5 37.5 11.9 <0.001
Female (%) 219 (52.3%) 95 (47.7%) 124 (56.4%) 0.079
Age of onset (y, mean SD) 17.0 10.2 17.2 10.9 (n¼ 188) 16.7 9.5 (n¼ 192) 0.648
YBOCS severity (mean SD) 20.0 7.9 19.9 7.6 (n¼ 195) 20.0 8.2 0.659
Positive family history of OC behavior (%) 64 (50.8) (n¼ 126)
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effect of the BDNF Met66 allele with a two times increased risk for
OCD in the BDNF Val66Met and Met66Met genotypes compared to
the Val66Val genotype in the case-control study was 99.9%, 92.0%,
and 95.8% in the total sample and males and females separately,
respectively. The power to detect a recessive effect of the BNDF
Met66 allele with a two times increased risk for OCD with the
BDNF Met66Met genotype compared to the BDNF Val66Met and
Val66Val genotypes was 34.0% in the total sample, 17.3% in males,
and 21.6% in females.
RESULTS
Demographic and clinical characteristics of the patients studied are
summarized in Table II. The Dutch patients were significantly older
than the South African patients (P< 0.001). The Dutch phenotyped
group contained significantly more women (P< 0.012) than the
South African group, although this difference did not reach signifi-
cance in the genotyped patients.
Case–Control Study
Genotype and allele frequencies, as well as case–control study
results are summarized in Table III. Genotype distribution was
in Hardy–Weinberg equilibrium for all groups. There was no
significant difference in genotype (P¼ 1.000) or allele frequency
(P¼ 0.926) between the South African and Dutch control groups,
nor were there differences in genotype or allele frequency between
male and female controls from South Africa and from the Nether-








exact test)Val66Val Val66Met Met66Met Val66 Met 66
Total cohort
OCD 260 (62.1%) 137 (32.7%) 22 (5.3%) 419 657 (78.4%) 181 (21.6%)
Control 428 (65.8%) 202 (31.1%) 20 (3.1%) 650 P¼ 0.149 1058 (81.4%) 242 (18.6%) P¼ 0.095
Male OCD 125 (62.5%) 65 (32.5%) 10 (5.0%) 200 315 (78.8%) 85 (21.3%)
Male control 183 (65.8%) 89 (32.0%) 6 (2.2%) 278 P¼ 0.234 455 (81.8%) 101 (18.2%) P¼ 0.247
Female OCD 135 (61.6%) 72 (32.9%) 12 (5.5%) 219 342 (78.1%) 96 (21.9%)
Female control 245 (65.9%) 113 (30.4%) 14 (3.8%) 372 P¼ 0.436 603 (81.0%) 141 (19.0%) P¼ 0.229
South African cohort
OCD 128 (64.3%) 62 (31.2%) 9 (4.5%) 199 318 (79.9%) 80 (20.1%)
Control 76 (66.1%) 36 (31.3%) 3 (2.6%) 115 P¼ 0.784 188 (81.7%) 42 (18.3%) P¼ 0.602
Male OCD 63 (60.6%) 34 (32.7%) 7 (6.7%) 104 160 (76.9%) 48 (23.1%)
Male control 21 (72.4%) 8 (27.6%) 0 (0.0%) 29 P¼ 0.350 50 (86.2%) 8 (13.8%) P¼ 0.147
Female OCD 65 (68.4%) 28 (29.5%) 2 (2.1%) 95 158 (83.2%) 32 (16.8%)
Female control 55 (64.0%) 28 (32.6%) 3 (3.5%) 86 P¼ 0.730 138 (80.2%) 34 (19.8%) P¼ 0.498
Dutch cohort
OCD 132 (60.0%) 75 (34.1%) 13 (5.9%) 220 339 (77.0%) 101 (23.0%)
Control 352 (65.8%) 166 (31.0%) 17 (3.2%) 535 P¼ 0.123 870 (81.3%) 200 (18.7%) P¼ 0.065
Male OCD 62 (64.6%) 31 (32.3%) 3 (3.1%) 96 155 (80.7%) 37 (19.3%)
Male control 162 (65.1%) 81 (32.5%) 6 (2.4%) 249 P¼ 0.887 405 (81.3%) 93 (18.7%) P¼ 0.914
Female OCD 70 (56.5%) 44 (35.5%) 10 (8.1%) 124 184 (74.2%) 64 (25.8%)
Female control 190 (66.4%) 85 (29.7%) 11 (3.8%) 286 P¼ 0.071 465 (81.3%) 107 (18.7%) P¼ 0.025
*P values <0.0025 were considered significant; P values below the nominal significance level of 0.05 are indicated in bold.
TABLE IV. Goodness of Fit Indices Obtained by Confirmatory Factor Analysis*
Fit index 1 factor model 2-factor model 3-factor model 4-factor model 5-factor model 6-factor model
CFI 0.506 0.715 0.845 0.853 0.881 0.889
TLI 0.650 0.802 0.891 0.897 0.916 0.920
RMSEA 0.110 0.083 0.062 0.060 0.054 0.053
SRMR 0.177 0.144 0.119 0.117 0.111 0.112
CFI, Comparative fit index; TLI, Tucker-Lewis Index; RMSEA, Root Mean Square Error of Approximation; SRMR, Standardized Root Mean Square Residual.
*Values of the CFI and of TLI approaching 0.95, values approaching 0.08 of the SRMR and values of the RMSEA< 0.05 are generally indicative of a good fit.
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TABLE V. Mean Factor Loadings for the Five Imputed Datasets Obtained by Confirmatory Factor Analysis*
Factor 1: Contamination and cleaning
Concern with dirt or germs 1.000
Excessive or ritualized hand washinga 0.851
Concerns or disgust with bodily waste or secretion (e.g., urine, faeces, and saliva) 0.772
Excessive concern with household items (e.g., cleaners, solvents)a 0.758
Excessive concern with environmental contaminants (e.g., asbestos, radiation, toxic waste) 0.743
Bothered by sticky substances or residues 0.712
Compulsions involving cleaning of household items or other inanimate objects 0.705
Other measures to prevent or remove contact with contaminants 0.696
Excessive or ritualized showering, bathing, teeth brushing, grooming, or toilet routine 0.684
Excessive concern with animals (e.g., insects) 0.676
Concerned that I will get ill because of contaminant 0.481
Concerned that I will get others ill by spreading contamination (aggressive)a 0.466
No concern with consequences of contamination other than how it might feela 0.390
Factor 2: Aggressive obsessions and checking
Fear that I will harm others because of not being careful enough (e.g., hit/run MVA) 1.000
Fear that I will steal things 0.738
Fear that I might harm others 0.720
Checking that I did not/will not harm others 0.707
Fear that I will act on unwanted impulses (e.g., to stab a friend) 0.696
Fear that I will be responsible for something else terrible happening (e.g., fire, burglary) 0.691
Fear of blurting out obscenities or insults 0.694
Checking that nothing terrible did/will happen 0.655
Fear of doing something else embarrassing 0.606
Fear that I might harm myself 0.537
Violent or horrific images 0.408
Checking that I did not/will not harm self 0.430
Checking that I did not make a mistake 0.428
Concerned that I will get others ill by spreading contamination (aggressive)a 0.361
Checking locks, stove, appliances, etc. 0.359
Factor 3: Symmetry obsessions, ordering, arranging, counting, and repeating compulsions
Ordering/arranging compulsions 1.000
Re-reading or re-writing 0.685
Counting compulsions 0.643
Symmetry obsessions 0.634
Need to repeat routine activities (e.g., in/out door, up/down from chair, i.e., repeating rituals) 0.537
Checking that I did not make a mistake 0.478
Checking locks, stove, appliances, etc. 0.293
Factor 4: Sexual an religious obsessions and compulsions
Forbidden or perverse sexual thoughts/images/impulses 1.000
Content (of obsession) involves children or incesta 0.842
Content (of obsession) involves homosexualitya 0.841
(Obsession with) sexual behavior toward others (aggressive)a 0.763
Excessive concern with right/wrong, morality 0.747
Concerned with sacrilege and blasphemy 0.691
Violent or horrific images 0.323
Factor 5: Hoarding obsessions and compulsions
Hoarding compulsions 1.000
Hoarding obsessions 0.931
Factor 6: Somatic obsessions and checking
Concern with illness or disease 1.000
Checking tied to somatic obsessions 0.711
Excessive concern with a body part or an aspect of appearance (e.g., dysmorphophobia) 0.620
Concerned that I will get ill because of contaminant 0.430
Checking that I did not/will not harm self 0.466
*Items shown in italic show high loadings on more than one factor.
aItem missing in the extended 80-item self report version.
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lands respectively (genotypes: P¼ 0.834 in males, and P¼ 0.920 in
males; alleles: P¼ 0.472 in males, P¼ 0.740 in females). Therefore,
these groups were pooled for the subsequent analyses. There was a
trend for an association between the BDNF Met66 allele and OCD in
female Dutch patients (P¼ 0.025). This was not found in the South
African sample or in the pooled sample.
Factor Analysis
YBOCS-CL data were available of 579 OCD patients. In the
exploratory factor analysis, thirteen factors with an eigenvalue> 1
were identified. Forty-three YBOCS-CL items were included in the
factor analysis, with the number of participants being higher than
the recommended 5–10 subjects per item. Based on the results from
the iterative exploratory factor analyses, we performed confirmatory
factor analyses to obtain a more parsimonious model. The fit indices
of the one to six factor models are summarized in IV. The one to six
factor models had an increasingly better fit. Since the seven factor
model did not converge, models with 7 or more factors were not
investigated.
The six factor model showed the best fit and fulfilled the criteria
for satisfactory model fit and was therefore used in subsequent
analyses. Factor loadings for this model are shown in Table V. This
model had the following factors:
Factor 1: Contamination obsessions and cleaning compulsions;
Factor 2: Aggressive obsessions and checking; Factor 3: Symmetry
obsessions, ordering, arranging, counting, and repeating compul-
sions; Factor 4: Sexual and religious obsessions; Factor 5: Hoarding
obsessions and compulsions; and Factor 6: Somatic obsessions and
checking.
Pearson’s correlations between mean scores per item for the
different factors and Cronbach’s alpha for internal consistency of
the different factors are summarized in Table VI. Although mean
scores per item for the different factors were significantly correlated
(data not shown), the correlations between them were relatively
low.
Genotype–Phenotype Correlations
Both genotype data and mean scores per item for the different
factors were available of 392 patients with OCD. The results of the
Kruskal–Wallis and Mann–Whitney U tests comparing mean
scores per item for the different factors between patients with
different genotypes are summarized in Table VII. None of the
factors showed an association with BDNF Val66Met genotype after
correction for multiple-testing. However, there was a trend for a
positive association between factor 4 (Sexual and religious
obsessions) and the BDNF Val66Val genotype in the patients.
The results of the comparisons of age of onset of OC symptoms
and OCD severity by BDNF Val66Met genotype are summarized in
Table VIII. There was a significant sex effect with respect to age of
onset of OC symptoms and genotype; age of onset of OC symptoms
in women with the BDNF Met66Met genotype was significantly
later than in the other groups (P¼ 0.002). Further, there was a trend
towards lower OCD severity in female patients with the BDNF
Val66Met or Met66Met genotypes compared to female patients
with the BDNF Val66Val genotype (P¼ 0.023).
There was no difference in genotype (P¼ 0.577) or allele fre-
quency (P¼ 0.282) between patients with and patients without a
positive family history of OC symptoms. However, none of the
women with the BNDF Met66Met genotype had a family history of
OC symptoms compared to 36.1% of the patients with other
genotypes (P¼ 0.019).
DISCUSSION
In this study, the BDNF Val66Met polymorphism was investigated
in a large group of patients with OCD. Female patients with the
BDNF Met66Met genotype had a later age of onset of OC symptoms
and there was a trend for a lower OCD severity in female patients
with one or more BDNF Met66 alleles. Moreover, female patients
with a negative family history of OC symptoms more often had the
BDNF Met66Met genotype. Although these results should be
considered preliminary, given the low number of female patients
with the BDNF Met66Met genotype (n¼ 12) and that data on age of
onset of OC symptoms were collected retrospectively, the findings
suggest that the BDNF Met66 alleles may have a protective role in
females with OCD. The finding of a protective effect of the BDNF
66Met allele is in line with a previous study (including patients of
both sexes) that found the BDNF 66Met alleles to be under-
transmitted in early onset OCD cases [Hall et al., 2003]. Early
onset seems to be linked to more severe OCD [Sobin et al., 2000;
Fontenelle et al., 2003]. Other studies in which no association was
found between the BDNF Val66Met variant and age of onset [Zai
et al., 2005; Wendland et al., 2007] had the drawback that smaller
TABLE VI. Mean Cronbach’s Alpha for the Different Factors and Perason’s Correlations for the Mean Score Per Item Between the
Different Factors
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6
Cronbach’s alpha 0.844 0.786 0.688 0.669 0.829 0.630
Factor 2 0.339 1.000
Factor 3 0.263 0.421 1.000
Factor 4 0.156 0.466 0.148 1.000
Factor 5 0.143 0.197 0.219 0.128 1.000
Factor 6 0.500 0.416 0.199 0.225 0.126 1.000
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samples were used which might have hampered power to detect
between-group differences.
Little is known about a sex-specific association between the
BDNF Val66Met polymorphism, OCD symptom severity and age
of onset of OC symptoms. To our knowledge, the only other study
that has directly investigated this, found an association between the
BDNF Met66 allele and an earlier age of onset of OCD in males
[Hemmings et al., 2008]. In apparent contrast, our findings sug-
gested a significant association between the BDNF Met66Met
genotype in females and later age of OC symptom onset, coupled
with a trend towards lower OC symptom severity. Our findings may
be analogous to animal studies that have suggested sex-dependent
differences in heterozygous BDNFþ/ knockout mice, with female
heterozygous BDNF/homozygous serotonin transporter gene
(5HTT)-knockout mice showing less increase in anxiety-like be-
haviors as well as less reduction of serotonin concentrations in
several brain regions than males [Ren-Patterson et al., 2006]. These
findings suggest that female sex may protect against reduced BDNF
function in mice, at least in the presence of 5HTT-deficiency. The
relationship between sex and serotonin levels might result from
differences in hormone status between men and women. In
estrogen-receptor b-knockout mice decreased concentrations of
serotonin and dopamine have been found, combined with in-
creased anxiety reactions, independent of current estradiol supple-
tion [Imwalle et al., 2005]. Moreover, it has been shown that
estrogen increased expression of tryptophan hydroxylase 2
(TPH2), the rate limiting enzyme in serotonin synthesis, in the
caudal region of the raphe nuclei of ovariectomized rats and that
expression of TPH2 mRNA in this region is correlated with anxiety-
like behavior [Hiroi et al., 2006]. Therefore, sex dependent effects
on anxiety symptoms might be the result of a serotonin enhancing
effect of estrogen at the level of the caudal raphe nuclei. Recently,
increasing evidence suggest that changes in the glutamatergic
system may be implicated in OCD [Pittenger et al., 2006]. BDNF
has been shown to influence the glutamatergic system by alteration
of the composition and plasticity of glutamatergic synapses
[Carvalho et al., 2008]. Therefore, the effects of the BDNF Val66Met
polymorphism may also be mediated by the glutamatergic pathway.
There are several lines of evidence in support of our findings
indicating that age of onset of OC symptoms and OCD symptom
severity are important aspects of the OCD phenotype that may have
specific genotypic underpinnings. Previous studies suggest that age
of onset in OCD has two distributions [Delorme et al., 2005].
Moreover, early onset OCD has been found to represent a more
familial phenotype of the disorder [Lenane et al., 1990; Pauls et al.,
1995; Delorme et al., 2005].
Item-level factor analysis of the YBOCS-CL identified six OCD
symptom dimensions. The contamination/cleaning, symmetry/
ordering, and hoarding symptom dimensions were similar to the
factors consistently found in previous category-based factor analy-
ses. The aggressive obsession/checking factor often found in
category-based factor analysis usually comprises aggressive, sexual,
and religious obsessions and in some studies this factor also
included somatic obsessions. In our item-level factor analysis, these
symptoms seemed to be divided over three factors: aggressive
obsessions/checking, sexual and religious obsessions and somatic
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We found a trend for higher mean score per item for Factor 4
(sexual and religious obsessions) in patients with the BDNF
Val66Val genotype than in patients with other genotypes. This
may suggest a protective effect for the BDNF Met66 alleles against
sexual and religious obsessions. This finding has to be considered
with caution however, since a considerable amount of missing data
were imputed for items in this factor. Two previous studies found
that the BDNF Val66Met polymorphism was not significantly
associated with any OCD symptom dimension [Wendland et al.,
2007; Alonso et al., 2008]. However, these studies comprised
smaller sample sizes, category-based analyses and only one study
specifically investigated the sexual and religious obsession symp-
tom category [Alonso et al., 2008].
A limitation of our study is the limited power to detect recessive
effects of the BDNF Met66 allele. Since the allele frequency of the
BDNF Met66 allele is low, larger sample sizes are needed to detect
recessive effects. Only the Val66Met polymorphism was investigat-
ed, which is a limitation of this study. To our knowledge, the
Val66Met polymorphism is the only known functional polymor-
phism in the BDNF gene. Therefore, we thought it was justified to
focus on this polymorphism only. A limitation of case–control
association studies is that these can be biased by population
stratification [Thomas and Witte, 2002]. Family-based studies
have been developed to circumvent this problem [Schulze and
McMahon, 2002]. Alternatively, multiple markers can be typed
to test and correct for possible population stratification by geno-
mic control or structured association methods [Pritchard and
Donnelly, 2001]. The use of these methods in future studies would
be desirable.
Further, gene–gene interactions that might confer increased risk
for OCD or dimensional OCD phenotypes were not investigated.
To our knowledge, only two studies investigated gene-gene
interaction involving the BDNF gene both with negative results.
Both studies have a relatively limited sample size, which may have
caused their negative results. The first study investigating interac-
tion between the BDNF Val66Met polymorphism and the 5HTT
gene promoter polymorphism found no evidence for a gene-gene
interaction in OCD [Wendland et al., 2007]. However, the negative
result of this study might have been the consequence of not taking
into account the effect of negative life events on the interaction
between the BDNF Val66Met and the 5HTTPR polymorphism, as
found in studies in depression [Kaufman et al., 2006; Kim et al.,
2007]. The second study investigated the interaction between the
BDNF gene and the gene encoding its specific receptor, the neuro-
trophic tyrosine kinase 2 gene (NTRK2) gene [Alonso et al., 2008].
In summary, studies investigating the role of gene-gene interaction
of the BDNF Val66Met polymorphism and other genes as well as
gene x environment interactions in the etiology of OCD are
warranted.
In conclusion, our results suggest that in females, the BDNF
Met66Met genotype may be associated with a late-onset form of
OCD and the BDNF Val66Val genotype with a more severe form of
OCD. Future studies including relevant variables such as sex, age of
onset, severity of OC symptoms and OC symptom dimensions
obtained by item level factor analysis in a sample large enough to
detect recessive effects of the BDNF Val66Met polymorphism are
needed to replicate and extend our current findings.
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